Ad-hoc | 26 January 2015 07:00

Cytos Biotechnology AG: Trading of Cytos shares and convertible bonds temporarily suspended.

Cytos Biotechnology AG / Key word(s): Miscellaneous

2015-01-26 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Cytos Biotechnology Ltd holds a Bondholders’ meeting today. Trading of Cytos shares and convertible bonds temporarily suspended.

Schlieren (Zurich), Switzerland, 26 January 2015, – Cytos Biotechnology Ltd (SIX:”CYTN”; the “Company”) holds today a meeting of the Bondholders to vote on the restructuring proposal for the convertible bonds, as announced on 6 January 2015. As the outcome of the meeting is unknown und such outcome may be price sensitive, Cytos has applied with the SIX Swiss Exchange to suspend trading of Cytos’ shares as well as Cytos’ convertible bonds from ten minutes prior to the start of the meeting (i.e. 12.50 CET) until at least one hour after the outcome of the meeting has been communicated by Cytos in a media release. The SIX Swiss Exchange has approved this request.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=KTKONWJAXQ
Document title: Cytos_Press_E_150126

2015-01-26 News transmitted by EQS Schweiz AG. www.eqs.com – news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

Language:	English
Company:	Cytos Biotechnology AG
	Wagistr. 25
	8952 Schlieren
	Switzerland
Phone:	+41 44 733 4747
Fax:	+41 44 733 4740
E-mail:	info@cytos.com
Internet:	www.cytos.com
ISIN:	CH0011025217, CH0029060735
Valor:	–
Listed:	Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX

End of News EQS Group News-Service

316091  2015-01-26